Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IRCT20181104041551N1 | Registry Identifier | Iranian Registry of Clinical Trials (IRCT) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no specific approach against the disease and mortality rate in severe cases is also significant. Therefore, finding effective treatment for the mortality of these patients is very important. In this study the investigators aim to determine the effect of Convalescent Plasma on COVID-19 patients Outcome through a Clinical Trial
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 Patients | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Convalescent Plasma | Biological | Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mortality changes in day 10 | Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time. | 10 days after plasma transmission |
| Mortality changes in day 30 | Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time. | 30 days after plasma transmission |
| Changes of C-reactive protein | Measurement of CRP | Day 1 |
| Changes of C-reactive protein | Measurement of CRP | Day 3 |
| Changes of C-reactive protein | Measurement of CRP | Day 7 |
| Changes of Interleukin 6 | Measurement of IL-6 | Day 1 |
| Changes of Interleukin 6 | Measurement of IL-6 | Day 3 |
| Changes of Interleukin 6 | Measurement of IL-6 | Day 7 |
| Changes of tumor necrosis factor-α |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of CD3 | Day 1 | |
| Changes of CD3 | Day 3 | |
| Changes of CD3 |
Not provided
Inclusion Criteria:
Recipient:
Donator:
Exclusion Criteria:
Recipient:
Donator:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Majid Saeedi, Ph.D. | Vice-Chancellor for Research, Mazandaran University of Medical Sciences | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imam Khomeini Hospital, Mazandaran University of Medical Sciences | Sari | Mazandaran | 4816633131 | Iran |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018352 | Coronavirus Infections |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Measurement of TNF-α |
| Day 1 |
| Changes of tumor necrosis factor-α | Measurement of TNF-α | Day 3 |
| Changes of tumor necrosis factor-α | Measurement of TNF-α | Day 7 |
| Changes of PaO2/FiO2 Ratio | Partial pressure of arterial oxygen/Percentage of inspired oxygen | Day 1 |
| Changes of PaO2/FiO2 Ratio | Partial pressure of arterial oxygen/Percentage of inspired oxygen | Day 3 |
| Changes of PaO2/FiO2 Ratio | Partial pressure of arterial oxygen/Percentage of inspired oxygen | Day 7 |
| Day 7 |
| Changes of CD4 | Day 1 |
| Changes of CD4 | Day 3 |
| Changes of CD4 | Day 7 |
| Changes of CD8 | Day 1 |
| Changes of CD8 | Day 3 |
| Changes of CD8 | Day 7 |
| Changes of CD4/CD8 ratio | Day 1 |
| Changes of CD4/CD8 ratio | Day 3 |
| Changes of CD4/CD8 ratio | Day 7 |
| Changes of lymphocyte count | Day 1 |
| Changes of lymphocyte count | Day 3 |
| Changes of lymphocyte count | Day 7 |
| Changes of leukocyte count | Day 1 |
| Changes of leukocyte count | Day 3 |
| Changes of leukocyte count | Day 7 |
| Changes of alanine transaminase (ALT) | Day 1 |
| Changes of alanine transaminase (ALT) | Day 3 |
| Changes of alanine transaminase (ALT) | Day 7 |
| Changes of aspartate transaminase (AST) | Day 1 |
| Changes of aspartate transaminase (AST) | Day 3 |
| Changes of aspartate transaminase (AST) | Day 7 |
| Changes of alkaline phosphatase (ALP) | Day 1 |
| Changes of alkaline phosphatase (ALP) | Day 3 |
| Changes of alkaline phosphatase (ALP) | Day 7 |
| Changes of lactate dehydrogenase (LDH) | Day 1 |
| Changes of lactate dehydrogenase (LDH) | Day 3 |
| Changes of lactate dehydrogenase (LDH) | Day 7 |
| Changes of creatine phosphokinase (CPK) | Day 1 |
| Changes of creatine phosphokinase (CPK) | Day 3 |
| Changes of creatine phosphokinase (CPK) | Day 7 |
| Changes of Creatine kinase-MB (CK-MB) | Day 1 |
| Changes of Creatine kinase-MB (CK-MB) | Day 3 |
| Changes of Creatine kinase-MB (CK-MB) | Day 7 |
| Changes of Specific IgG | Day 1 |
| Changes of Specific IgG | Day 3 |
| Changes of Specific IgG | Day 7 |
| Radiological findings | Computed tomography Scan and Chest X-Ray | Within 2 hours after admission |
| Radiological findings | Computed tomography Scan and Chest X-Ray | Day 14 |
| Number of days ventilated | Through study completion, an average of 2 weeks |
| Length of hospitalization | Through study completion, an average of 2 weeks |
| D007239 |
| Infections |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |